 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
ARIPIPRAZOLE: AN
ANTIPSYCHOTIC WITH A NOVEL MECHANISM OF ACTION
Amy A
Lemieux, Jennifer D Goldman-Levine, and Jessica L Goren
To order the complete CE article click here.
To request full article click here.
OBJECTIVE: To evaluate aripiprazole in the treatment of schizophrenia, including a comparison of available agents, pharmacology, pharmacokinetics, assessment of clinical trials, and adverse effects.
DATA SOURCES: A MEDLINE search (1962–March 2003) was conducted for primary and secondary sources. Search terms included OPC-14597, aripiprazole, typical antipsychotics, atypical antipsychotics, and schizophrenia. The Review and Evaluation of Clinical Data from NDA 21-436 was accessed from the FDA Web site.
STUDY SELECTION: All articles retrieved were evaluated, and the most appropriate studies were selected. Relevant poster presentations were included.
DATA SYNTHESIS: Aripiprazole is a potent partial agonist/antagonist at the dopamine D2 receptor, as well as a partial agonist at the serotonin 5-HT1A receptor and an antagonist at the 5-HT2A receptor. Clinical trials were assessed for information on dosing, side effects, and adverse drug reactions.
CONCLUSIONS: Aripiprazole appears to be superior to placebo for the treatment of schizophrenia, with a favorable adverse effect profile.
J Pharm Technol 2003;19:365-72.
ACPE Universal Program Number: 407-000-03-055-H01
To order the complete CE article click here.
To request full article click here.
|
|
|
||
|
